Launch of Phase 3 clinical trial with Nefecon in Japan

Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan - Calliditas Therapeutics AB Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy inJapan- Calliditas Therapeutics AB *Japan Intractable Disease Information Center CONTACT: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email:...

STOCKHOLM, 04/07/2024 (informazione.it - comunicati stampa - scienza e tecnologia)

Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan - Calliditas Therapeutics AB

*Japan Intractable Disease Information Center

Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/launch-of-phase-3-clinical-trial-with-nefecon-in-japan,c4011121

The following files are available for download:

 

View original content: https://www.prnewswire.co.uk/news-releases/launch-of-phase-3-clinical-trial-with-nefecon-in-japan-302189479.html